906794-87-4

Upstream product

• 65515-28-8 methyl 2,6-dichloronicotinate 
• 106-48-9 4-chloro-phenol 

Downstream Products

• 925207-28-9 methyl 6-(4-chloro-phenoxy)-2-propylnicotinate 
• 948897-70-9 C₇H₈O₃S*C₂₁H₁₆Cl₂N₂O₃ 
• 948897-66-3 (2S)-2-({6-chloro-3-[6-(4-chlorophenoxy)-2-propylpyridin-3-yl]-1,2-benzisoxazol-5-yl}oxy)propanoic acid tosylate salt 
• 948897-60-7 (2S)-2-({6-chloro-3-[6-(4-chlorophenoxy)-2-propylpyridin-3-yl]-1,2-benzisoxazol-5-yl}oxy)propanoic acid benzenesulfonate salt 
• 948897-63-0 C₂₁H₁₇Cl₂NO₄ 
• 948897-62-9 C₂₃H₂₁Cl₂NO₄ 
• 948897-61-8 C₁₅H₁₄ClNO₃ 
• 909543-30-2 (2S)-2-({6-chloro-3-[6-(4-chlorophenoxy)-2-propylpyridin-3-yl]-1,2-benzisoxazol-5-yl}oxy)propanoic acid 

Relevant academic research and scientific papers

Highly regioselective DABCO-catalyzed nucleophilic aromatic substitution (SNAr) reaction of methyl 2,6-dichloronicotinate with phenols

Exclusive formation of 6-aryloxy ethers 9 from an SNAr reaction of methyl 2,6-dichloronicotinate (2) with phenols 7 catalyzed by 1,4-diazabicyclo[2.2.2]octane (DABCO) in the presence of stoichiometric triethylamine is described. The reaction pr

COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF

The present invention relates to a compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, a preparation method thereof and a pharmaceutical use thereof. In particular, the compound has the following Formula (I), wherein R2

NOVEL CRYSTALLINE SALT FORM OF AN ANTIDIABETIC COMPOUND

A novel crystalline anhydrous toluenesulfonic acid salt form of a selective PPAR gamma partial agonist which has a fused bicyclic aromatic group attached to an oxypropanoic acid moiety is stable and non-hygroscopic. The crystalline salt form is useful for

ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES

Pyridinyloxyphenyl and pyridinyloxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dy

NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS

A novel crystalline anhydrate of the free acid and a crystalline anhydrous besylate salt of a selective PPAR gamma partial agonist which has a fused bicyclic aromatic group attached to an oxypropanoic acid moiety are stable and non-hygroscopic. The compou

FUSED AROMATIC COMPOUNDS HAVING ANTI-DIABETIC ACTIVITY

Fused aromatic compounds of Formula (I) are PPAR gamma agonists or partial agonists and are useful in the treatment or control of type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obes